CTOs on the Move

Vestaron

www.vestaron.com

 
Recent winner of the Green Chemistry award, Vestaron is leading a peptide-based revolution in crop protection. We are committed to providing growers with novel, effective chemistries that address proven targets. Our peptides overcome existing resistance issues while offering a desired safety profile for workers, beneficials and the environment. Initially, Vestaron is focused on a class of peptides that kills insect pests efficiently, but is safe for humans, birds, fish, pollinators and the environment. As part of this, the company has developed a proprietary platform for peptide optimization and fermentation-based peptide production that will allow development of a wide variety of ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.vestaron.com
  • 600 Park Offices Drive Suite 117
    Durham, NC USA 27709
  • Phone: 919.694.1022

Executives

Name Title Contact Details

Funding

Vestaron raised $40M on 06/10/2019
Vestaron raised $18.3M on 02/11/2021

Similar Companies

Molecular Pharmacology Limited (USA)

Molecular Pharmacology Limited (USA) is a West Hollywood, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Replimune

Replimune is creating a new class of oncolytic immunotherapy designed to ignite a powerful immune response to treat cancer and vaccinate against future relapse. Replimune`s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response. Replimune is pioneering the development of novel tumor-directed oncolytic immunotherapies. We imagine a world where cancer is a curable disease.

Avalon Pharmaceuticals

Avalon Pharmaceuticals , Inc. is a Germantown, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tri-Source Pharma

Tri-Source Pharma is a pharmaceutical manufacturer/distributor operating in both the human and animal health care industries.

Lyell

We are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. While enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. Cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. Our goal is nothing less than to develop curative cell-based therapies for solid tumor cancers.